The Lemon Fool

LYNPARZA MEETS PRIMARY ENDPOINT IN PHASE III TRIAL IN BRCA-MUTATED METASTATIC BREAST CANCER

"AstraZeneca today announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician's choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations. Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin)."

http://www.investegate.co.uk/astrazenec ... 00061622X/

I don't really know enough about cancer treatment to determine the implications for AZN's bottom line, but 'better survival chances than chemo' certainly sounds promising - for the both the bottom line and society in general. I hope this translates into a successful life saving drug and profits flow as a well deserved consequence.

People deserve a better cancer treatment than chemotherapy. I hope the solution is found as soon as possible.